STOCK TITAN

SHC Form 144 Filed for 126,611-Share Insider Sale on Nasdaq

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sotera Health Company (SHC) filing a Form 144 notifies the proposed sale of 126,611 shares of common stock through Charles Schwab with an aggregate market value of $2,040,969. The shares represent part of equity compensation originally acquired from the issuer on 11/20/2020 and are scheduled for sale approximately on 08/22/2025 on Nasdaq.

The filing discloses the number of shares outstanding as 284,046,606, and states there were no reported sales by the person in the past three months. The filer certifies they have no undisclosed material adverse information. This is a routine Rule 144 notice of an insider-proposed sale of previously issued equity compensation.

Positive

  • None.

Negative

  • Proposed insider sale of 126,611 shares valued at $2,040,969 is disclosed (a factual observation of insider selling).

Insights

TL;DR: Routine insider sale notice of equity compensation; size is small relative to total shares outstanding.

The Form 144 reports an intended sale of 126,611 shares valued at $2.04 million. Versus the reported 284.05 million shares outstanding, the sale equals approximately 0.045% of outstanding common stock, which is immaterial from a dilution or market-supply perspective. The securities were acquired as equity compensation on 11/20/2020 and the filing indicates no other sales in the prior three months. From a financial-impact standpoint, this notice is informational and unlikely to affect company valuation.

TL;DR: Disclosure meets Rule 144 procedural requirements; the signer affirms absence of undisclosed material information.

The filing provides required broker, share count, acquisition date, and nature of acquisition (equity compensation). The signer’s certification that they are unaware of undisclosed material adverse information is standard language and relevant for compliance. No trading plan or 10b5-1 adoption date is indicated. Governance-wise, the notice documents regulator-compliant insider activity but does not reveal material corporate developments.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Sotera Health's (SHC) Form 144 disclose?

The Form 144 discloses a proposed sale of 126,611 shares of common stock through Charles Schwab, with an aggregate market value of $2,040,969, approximately on 08/22/2025.

When were the shares that are being sold acquired?

The shares were acquired on 11/20/2020 as equity compensation from the issuer.

How many shares outstanding does the filing report for SHC?

The filing reports 284,046,606 shares outstanding.

Has the person sold SHC securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Does the filing state any undisclosed material information about Sotera Health?

By signing, the person represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.